Elanco finalizes Novartis Animal Health acquisition
Deal allows the company to offer a diversified product range and capabilities to help customers grow their businesses
Elanco has finalized the acquisition of Novartis Animal Health. With the deal, Elanco will offer a portfolio of nearly 300 brands encompassing therapeutics, vaccines, parasiticides, antimicrobials, food safety, surgical, enzymes and more.
The acquisition, announced in April, follows Elanco’s purchase of Lohmann Animal Health earlier in 2014. Both strategic investments allow the company to provide a more diversified product offering and capabilities to help customers sustain and grow their businesses.
“Elanco’s acquisition of Novartis Animal Health brings together two strong companies with a passion for serving the customer,” said Rob Aukerman, president North American Commercial Operations for Elanco. “We will continue to offer the products our customers trust, while significantly investing in the development of new solutions to our customers’ greatest unmet needs.”
In the future, Elanco will increase investment in research and development. The combined organization will have expanded capabilities and expertise with numerous product development projects focused on:
• protecting livestock from disease and parasites, improving animal well-being and reducing the environmental footprint of livestock production
• providing a broader set of solutions in areas such as enzymes, diagnostics, aquaculture and vaccines
• enhancing care and extending quality of life of pets, while preventing disease and protecting from parasites
“We’ll continually seek innovative ways we can support our customers’ business,” Aukerman said. “With increased technical services that combine our analytic and benchmarking tools with on-the-ground support, we'll be able to spend more time with individual customers seeking innovative solutions that can make a difference in their business.”